VR Adviser’s Sagimet Biosciences SGMT Stock Holding History

VR Adviser’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-515,000	Closed	-$4.53M	–	41
2023 Q3	$4.53M	Buy	+515,000	New	+$6.86M	0.48%	32

Other funds holding SGMT

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser's SGMT Position: Q4 2023 in Review

VR Adviser sold out of Sagimet Biosciences (SGMT) in Q4 2023, closing a stake of 515,000 shares — an estimated $4.53M sold.

VR Adviser first reported a position in SGMT in Q3 2023 and held it in 1 quarter. The position peaked at $4.53M in Q3 2023. 51 funds tracked by Wall St. Rank hold SGMT as of Q4 2023.

VR Adviser reported no remaining Sagimet Biosciences position as of Q4 2023 after selling out during the quarter.
VR Adviser sold 515,000 Sagimet Biosciences shares in Q4 2023, an estimated $4.53M.
VR Adviser first reported a position in Sagimet Biosciences in Q3 2023 and held it in 1 quarter.
VR Adviser's Sagimet Biosciences position peaked at $4.53M in Q3 2023.
51 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q4 2023.

Based on VR Adviser's 13F filing for Q4 2023, filed 14 Feb 2024.